¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Sodium Pyrophosphate Anhydrous"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • sodium carrier
    ³ªÆ®·ý¿î¹Ýü(¡­ê¡Úæô÷).
  • sodium channel
  • sodium chloride
    ¿°È­³ªÆ®·ý
  • sodium chloride balance test
    ¿°È­³ªÆ®·ýÆòÇü½ÃÇè(¡­øÁû¬ãËúÐ).
  • sodium chloride poisoning
    ¿°È­³ªÆ®·ýÁßµ¶Áõ(¡­ñéÔ¸ñø).
  • sodium chloride poisoning
    ¿°È­³ªÆ®·ýÁßµ¶Áõ(¡­ñéÔ¸ñø)
  • sodium deficit
    ³ªÆ®·ý°áÇÌ(Áõ)(¡­ÌÀù¹ñø).
  • sodium desoxycholate
    µ¥¼Ó½ÃÄݸ¯¿°
  • sodium dodecyl sulfate
    ¼Òµð¿òµµµ¥½Ç¼³ÆäÀÌÆ®
  • sodium excreting factor
    ³ªÆ®·ý¹è¼³ÀÎÀÚ (¡­ÛÉàÜì×í­).
  • sodium fluoride
    ºÒÈ­³ªÆ®·ý
  • sodium hippurate hydrolysis test
    È÷Ǫ¸£»ê[¸¶´¢»ê]³ªÆ®·ý °¡¼öºÐÇØ½ÃÇè
  • sodium hydroxide
    ¼ö»êÈ­³ªÆ®·ý
  • sodium iodide
    ¿äµåÈ­³ªÆ®·ý
  • sodium lactate solution, Hartmann
    Á£»ê³ªÆ®·ý¿ë¾×, Çϸ£Æ®¸¸¿ë¾×, À¯»ê³ªÆ® ·ý¿ë¾×.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CPPD calcium pyrophosphate dihydrate deposition [syndrome]; cisplatin; cost per patient day
IPP independent practice plan; individual patient profile; inflatable penile prosthesis; inorganic pyrop...
LTPP lipothiamide pyrophosphate
PP diphosphate group; emphysema [pink puffers]; near point of accommodation [Lat. punctum proximum]; pa...
PP1 free pyrophosphate
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PPi Pyrophosphate
PPi-PFK Pyrophosphate-dependent phosphofructokinase
Tc-PYP Technetium 99m pyrophosphate
Tc-99m PYP Technetium-99m pyrophosphate
TPP Thiamin pyrophosphate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • sodium perborate
    °úºØ»ê ³ªÆ®·ý
    ºØ»êÀ̳ª ºØ»ê³ªÆ®·ýÀÌ ³ªÆ®·ý ¶Ç´Â °ú»êÈ­ ¼ö¼Ò¿Í »óÈ£ÀÛ¿ëÇÏ¿© »ý¼ºµÈ È­ÇÕ¹°, ¹æºÎÁ¦. 2% ¿ë¾×À¸·Î´Â ¾çÄ¡Áú ¾×À¸·Îµµ »ç¿ëµÈ´Ù.
  • sodium phosphate
    ÀÎ»ê ³ªÆ®·ý
    µ¿ÀǾî=disodium hydrogen
  • sodium polystyrene sulfonate
    Æú¸®½ºÅ¸À̸° ¼³Æù ³ªÆ®·ý
    ³ªÆ®·ý ÇüÅÂÀÇ ¾çÀ̿ ±³È¯ ¼öÁö 1g´ç ¹«¼ö±âÀÇ Ä®·ý 110-135mg °ú ±³È¯. °úÄ®·ý Ç÷Áß Ä¡·á¿¡ »ç¿ëÇÑ´Ù.
  • sodium pump
    ³ªÆ®·ý ÆßÇÁ
  • sodium salicylate
    »ì¸®½Ç»ê ³ªÆ®·ý
    ¹«Á¤ÇüÀÇ °áÁ¤¼º ºÐ¸» ¶Ç´Â Àμ³·Î¼­ Á¸ÀçÇÑ´Ù. ÁøÅëÁ¦, ÇØ¿­Á¦, Ç×°üÀý¿°Á¦·Î »ç¿ëµÇ¸ç °æ±¸ÀûÀ¸·Î Åõ¿©µÈ´Ù.
  • sodium sulfate
    Ȳ»ê ³ªÆ®·ý
    ¹Ù·ý Áßµ¶¿¡ ´ëÇÑ ÇØµ¶Á¦ ¼³»ç ¾àÀ¸·Î »ç¿ëÇϸç, °¨¿°µÈ »óó¿¡ ´ëÇÑ ÃÖ¸²ÇÁ ¾àÀ¸·Î¼­ ±¹¼ÒÀûÀ¸·Î »ç¿ëÇϱ⵵ ÇÑ´Ù.
  • sodium tertiary phosphate
    Á¦ 3ÀÎ »ê³ªÆ®·ý
    Ca3
  • sodium tetradecyl sulfate
    Åׯ®¶óµ¥½ÇȲ»ê³ªÆ®·ý
    °æÈ­¼ºÀ» °®´Â À½À̿ °è¸éȰ¼ºÁ¦, ¹é»öÀÇ ¹Ð¶ø¼º °íü. ½ÀÀ±Á¦·Î¼­ ¾²À̸ç, Á¤¸Æ·ù¿Í Ä¡ÁúÀÇ Ä¡·á·Îµµ »ç¿ëÇÑ´Ù.
  • sodium transport system
    ³ªÆ®·ý ¿î¹Ý°è
  • sodium-potassium exchange resin
    ¼Òµð¿ò-Æ÷Ÿ½· ±³È¯ ¼öÁö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
uridine 5'-(alpha-D-galactopyranosyl pyrophosphate) NAD 2-hexosyl oxidoreductase <enzyme> Converts udpgalactose (pyranose form) to 2-keto-galactose which rearranges to furanose form
Chemical name: UDPgalactose nad 2-hexosyl oxidoreductase
Registry number: EC 1.1.1.-
(26 Jun 1999)
5-phospho-alpha-d-ribosyl 1-pyrophosphate 5-Phosphoribosyl 1-diphosphate;d-Ribose carrying a phosphate group on ribose carbon-5 and a pyrophosphate group on ribose carbon-1; an intermediate in the formation of the pyrimidine and purine nucleotides as well as NAD+.
Synonym: 5-phosphoribose 1-diphosphate.
Acronym: PRPP
(05 Mar 2000)
99mTc pyrophosphate A radionuclide tracer used for imaging ischemic myocardium in nuclear medicine.
See: technetium-99m.
(05 Mar 2000)
lipothiamide pyrophosphate Name once given to the coenzymes of the multi-enzyme complex catalyzing the formation of acetyl-CoA from pyruvate and involving lipoamide and thiamin pyrophosphate, on the assumption that they were a single compound.
See: lipoic acid.
(05 Mar 2000)
acetosulfone sodium 2-N-Acetylsulfamyl-4,4'-diaminodiphenylsulfone;a leprostatic administered orally.
(05 Mar 2000)
acetrizoate sodium Salt of 3-acetamido-2,4,6-triiobenzoic acid, a formerly used water-soluble radiographic contrast medium.
(05 Mar 2000)
antimony sodium gluconate <chemical> Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.
Pharmacological action: antiprotozoal agents, schistosomicides.
(12 Dec 1998)
antimony sodium tartrate Na(SbO)C4H4O6;used in the treatment of schistosomiasis, and as an emetic.
Synonym: sodium antimonyl tartrate.
(05 Mar 2000)
antimony sodium thioglycollate A compound of antimony trioxide and thioglycolic acid, used for tropical parasites.
(05 Mar 2000)
azlocillin sodium Sodium (6R)-6-[d-2-(2-oxoimidazolidine-1-carboxamido)-2-phenylacetamido]penicillanate;an extended spectrum penicillin used in treatment of infections caused by Pseudomonas aeruginosa, Escherichia coli, and Haemophilus influenzae.
(05 Mar 2000)
bismuth sodium tartrate A basic sodium bismuth tartrate; an antisyphilitic agent.
(05 Mar 2000)
bismuth sodium triglycollamate Sodium bismuth complex of nitrilotriacetic acid.
(05 Mar 2000)
caffeine and sodium benzoate A mixture of equal parts of sodium benzoate and caffeine, used to meet the indication of caffeine.
(05 Mar 2000)
caffeine and sodium salicylate A mixture of sodium salicylate and caffeine used for the relief of headache and neuralgia.
(05 Mar 2000)
meclofenamate sodium Monosodium N-(2,6-dichloro-m-tolyl)anthranilate monohydrate;a non-steroidal anti-inflammatory agent with analgesic and antipyretic actions.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á